Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease.

Cyclosporin (7.5 mg/kg daily) was given to 8 AIDS patients for 17-66 days and to 25 HIV-seropositive non-AIDS patients, 15 with stage II (T4 cells/microliter greater than or equal to 300, less than 600) and 10 with stage III (T4/microliter less than 300), for 3-6 months with the hypothesis that the drug could inhibit both HIV replication and the potential autoimmune component of HIV disease. A sustained increase over 600 T4/microliter occurred in 7 patients with stage II and 1 with stage III. T8 cells significantly decreased in most patients and lymphadenopathy disappeared in 14/16. After cyclosporin withdrawal T4 and T8 cells as well as lymphadenopathy returned to pretreatment status. Cyclosporin side effects (hypertension, creatinine increase, and anemia) were moderate and reversible. These results might stimulate biological research as well as clinical trials with cyclosporin in selected groups of HIV-seropositive subjects with the aim of delaying or preventing AIDS occurrence.

[1]  P. M. Chisholm,et al.  Does cyclosporine act in vivo as it does in vitro? , 1986, Immunology today.

[2]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.

[3]  D. Stites,et al.  Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. , 1986, Clinical immunology and immunopathology.

[4]  T. Strom,et al.  Cyclosporine: a new immunosuppressive agent for organ transplantation. , 1984, Annals of internal medicine.

[5]  A. Laupacis,et al.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. , 1984, Science.

[6]  D. Fuchs,et al.  HIV INFECTION IN RENAL ALLOGRAFT RECIPIENTS , 1986, The Lancet.

[7]  Richards Bw.  Sjogren-Larsson syndrome. , 1970, Lancet.

[8]  E. Helm,et al.  [Spontaneous course of LAV/HTLV-III infection. Follow-up of persons from AIDS-risk groups]. , 2008, Deutsche medizinische Wochenschrift.

[9]  Susan E. Wilson,et al.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. , 1986, Science.

[10]  J. Strominger,et al.  Biology of the human histocompatibility leukocyte antigen (HLA) system and a hypothesis regarding the generation of autoimmune diseases. , 1986, The Journal of clinical investigation.

[11]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[12]  A. Schwarz,et al.  HTLV-III INFECTION IN KIDNEY TRANSPLANT RECIPIENTS , 1985, The Lancet.

[13]  E. Reinherz,et al.  Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins. , 1983, Journal of immunology.

[14]  C. Auffray,et al.  Speculations on sequence homologies between the fibronectin cell-attachment site, major histocompatibility antigens, and a putative AIDS virus polypeptide. , 1986, Human immunology.

[15]  JohnJ. Brooks.  KAPOSI'S SARCOMA: A REVERSIBLE HYPERPLASIA , 1986, The Lancet.

[16]  T. Strom,et al.  Sparing of suppressor cells: a critical action of cyclosporine. , 1984, Transplantation.

[17]  A. Fauci,et al.  Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. , 1986, Science.

[18]  The effects of cyclosporin A on the immune system. , 1985, Annual review of immunology.

[19]  H. Panitch,et al.  Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. , 1976, Laboratory investigation; a journal of technical methods and pathology.

[20]  R. Zinkernagel,et al.  Suppression by cyclosporin A of murine T-cell-mediated immunity against viruses in vivo and in vitro. , 1985, Cellular immunology.

[21]  D. Stites,et al.  Hypothesis: AIDS is an autoimmune disease directed at the immune system and triggered by a lymphotropic retrovirus. , 1986, Clinical immunology and immunopathology.

[22]  K. Mills.  Processing of viral antigens and presentation to class II-restricted T cells. , 1986, Immunology today.

[23]  Baig Ar,et al.  Sex-chromatin values in rat epithelium. , 1967 .

[24]  J. Phair,et al.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. , 1987, The New England journal of medicine.

[25]  G. B. Dowling,et al.  Vitamin D in cutaneous tuberculosis. , 1947, Lancet.

[26]  J. Goedert,et al.  Epidemiology of human T-lymphotropic virus type III and the risk of the acquired immunodeficiency syndrome. , 1985, Annals of internal medicine.

[27]  D. Crawford,et al.  IMMUNITY TO EPSTEIN-BARR VIRUS IN CYCLOSPORIN A-TREATED RENAL ALLOGRAFT RECIPIENTS , 1982, The Lancet.

[28]  E. Gelmann,et al.  ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1986, The Lancet.

[29]  K. Herold,et al.  Immunosuppressive effects of cyclosporin A on cloned T cells. , 1986, Journal of immunology.

[30]  J. Goedert,et al.  Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. , 1987, JAMA.

[31]  G. Karsenty,et al.  CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET Results of a Multicentre Double-blind Trial , 1986, The Lancet.